Two years ago South African company MJ MEDTECH a subsidiary of WUHAN GENERAL GROUP INC. announced plans to enter psychedelic sector after successful cannabis and CBD endeavors. Tests are now complete for rat and cell line trials, with the focus now being pushed towards analyzing the data and putting it into meaningful words that can show the true applications of psilocybin, which is produced by specific types of mushrooms that originate from spores. They are testing for brain chemistry, inflammation, overall health and long term affects. The goal of these studies is to prove the efficacy of psilocybin as a treatment for mental health (ptsd, depression, anxiety, etc) as well as other physical ailments (high blood pressure, brain inflammation etc). Human trials are now being scheduled in accordance with Covid 19 limitations. They currently have several successful cannabis products and will follow suit with extracts and fruiting bodies when testing is complete.
Related Articles
The Curious Case of the Grey-Market Mushroom Edibles
The views and opinions expressed in this piece are solely those of the author, and are not representative of Inoculate the World as a company. "Magic Mushroom" Edibles are Everywhere. What's the Deal? Six years ago, very few American psychedelic users had...
The Path Forward for Psychedelic Therapy
Everyone’s talking about the psychedelic renaissance, and the medical applications for psychedelics are a huge part of that discussion. Psychedelic legalization has been a winding path in the United States. The War on Drugs of the 1960s ushered in a ‘psychedelic dark...
The Rising Potential of Indigenous African Mushroom Cultivation
When we think of gourmet mushrooms, we typically think of the classics: oyster mushrooms (Pleurotus ostreatus) and shiitake (Lentinula edobes), or perhaps the lesser-known but equally delicious chestnut mushrooms (Pholiota adiposa). Beyond this familiar lineup,...